Evidence map›Paper›PMID 40744810›Full record

ArticleCancer research and treatment2026

Real-World Efficacy and Safety of Teclistamab for Patients with Relapsed or Refractory Multiple Myeloma: Nationwide Retrospective Analysis of the Named Patient Program in Korea.

Jun Ho Yi, Jae Hoon Lee, Sung-Hoon Jung, Ji Hyun Lee, Ji Yun Lee, Kihyun Kim, Sung-Soo Park, Chang-Ki Min, Yoon Seok Choi, Min Kyoung Kim and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jun Ho YiDivision of Hematology-Oncology, Department of Medicine, Chung-Ang University Hospital, Seoul, Korea.
Jae Hoon LeeDepartment of Hematology, Gachon University College of Medicine, Incheon, Korea.
Sung-Hoon JungDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Korea.
Ji Hyun LeeDepartment of Internal Medicine, Dong-A University College of Medicine, Busan, Korea.
Ji Yun LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
Kihyun KimDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sung-Soo ParkDepartment of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Chang-Ki MinDepartment of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Yoon Seok ChoiDepartment of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
Min Kyoung KimDivision of Hemato-Oncology, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Ho-Young YhimDepartment of Internal Medicine, Jeonbuk National University Medical School, Jeonju, Korea.
Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. dhyoon@amc.seoul.kr.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe prognosis for heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) remains poor. Teclistamab, a bispecific antibody targeting B-cell maturation antigen and CD3, has demonstrated deep and durable responses in triple-class-exposed RRMM patients in the MajesTEC-1 trial. To further evaluate the efficacy and safety of teclistamab in Korean patients, we conducted a nationwide retrospective analysis. MATERIALS AND

methodsIn August 2022, a Named Patient Program for teclistamab was initiated in Korea. The inclusion and exclusion criteria, dosage, treatment schedule, and dose modification protocols were largely consistent with those of the MajesTEC-1 trial. Retrospective data were collected for 42 patients who participated in the program.

resultsThe median age was 67 years (range, 48 to 84 years), and the median number of prior lines of therapy was 6 (range, 3 to 10). Triple- and penta-class refractoriness were observed in 40.5% and 19.0% of patients, respectively. The overall response rate was 66.7% (28/42); 17 patients (40.5%) achieved a complete or deeper response. With a median follow-up of 16.4 months, the median progression-free survival (PFS) was 14.1 months. Patients with revised International Staging System stage III exhibited significantly shorter PFS (3.1 months vs. not reached, p=0.041). The 12-month overall survival rate was 61.7%; disease progression and infection were the most common causes of death. Only one patient experienced grade ≥ 3 cytokine release syndrome (CRS), and no cases of immune effector cell-associated neurotoxicity syndrome were reported. Grade ≥ 3 infections occurred in 42.9% (n=18) of patients and frequently led to treatment interruption (n=18).

conclusionEfficacy outcomes including rapid responses, a high response rate, and prolonged survival duration as well as safety profiles, including the incidence of infections, CRS were comparable to those observed in the MajesTEC-1 trial. Given the historically poor outcomes observed in patients with triple-class-exposed RRMM, teclistamab treatment should be strongly considered for these patients.

Indexed as

Antibodies, BispecificAntineoplastic Agents, ImmunologicalMultiple MyelomaNeoplasm Recurrence, LocalAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRepublic of KoreaRetrospective StudiesTreatment OutcomeAntibodies, BispecificAntineoplastic Agents, ImmunologicalBispecific antibodyMultiple myelomaTeclistamab

Identifiers

PMID40744810
PMCPMC13382543

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.